S&P 500   2,978.76 (-4.42%)
DOW   25,766.64 (-4.42%)
QQQ   205.64 (-5.01%)
AAPL   273.52 (-6.54%)
FB   189.75 (-3.78%)
MSFT   158.18 (-7.05%)
GOOGL   1,314.95 (-5.43%)
AMZN   1,884.30 (-4.81%)
CGC   18.44 (-6.96%)
NVDA   252.60 (-5.62%)
BABA   205.03 (-1.78%)
MU   50.58 (-3.42%)
GE   10.39 (-5.11%)
TSLA   679.00 (-12.81%)
AMD   44.01 (-7.33%)
T   35.73 (-3.69%)
ACB   1.45 (-3.97%)
F   6.97 (-3.33%)
NFLX   371.71 (-1.99%)
PRI   114.78 (-4.46%)
BAC   29.13 (-4.90%)
DIS   118.04 (-4.31%)
GILD   72.66 (-2.73%)
S&P 500   2,978.76 (-4.42%)
DOW   25,766.64 (-4.42%)
QQQ   205.64 (-5.01%)
AAPL   273.52 (-6.54%)
FB   189.75 (-3.78%)
MSFT   158.18 (-7.05%)
GOOGL   1,314.95 (-5.43%)
AMZN   1,884.30 (-4.81%)
CGC   18.44 (-6.96%)
NVDA   252.60 (-5.62%)
BABA   205.03 (-1.78%)
MU   50.58 (-3.42%)
GE   10.39 (-5.11%)
TSLA   679.00 (-12.81%)
AMD   44.01 (-7.33%)
T   35.73 (-3.69%)
ACB   1.45 (-3.97%)
F   6.97 (-3.33%)
NFLX   371.71 (-1.99%)
PRI   114.78 (-4.46%)
BAC   29.13 (-4.90%)
DIS   118.04 (-4.31%)
GILD   72.66 (-2.73%)
S&P 500   2,978.76 (-4.42%)
DOW   25,766.64 (-4.42%)
QQQ   205.64 (-5.01%)
AAPL   273.52 (-6.54%)
FB   189.75 (-3.78%)
MSFT   158.18 (-7.05%)
GOOGL   1,314.95 (-5.43%)
AMZN   1,884.30 (-4.81%)
CGC   18.44 (-6.96%)
NVDA   252.60 (-5.62%)
BABA   205.03 (-1.78%)
MU   50.58 (-3.42%)
GE   10.39 (-5.11%)
TSLA   679.00 (-12.81%)
AMD   44.01 (-7.33%)
T   35.73 (-3.69%)
ACB   1.45 (-3.97%)
F   6.97 (-3.33%)
NFLX   371.71 (-1.99%)
PRI   114.78 (-4.46%)
BAC   29.13 (-4.90%)
DIS   118.04 (-4.31%)
GILD   72.66 (-2.73%)
S&P 500   2,978.76 (-4.42%)
DOW   25,766.64 (-4.42%)
QQQ   205.64 (-5.01%)
AAPL   273.52 (-6.54%)
FB   189.75 (-3.78%)
MSFT   158.18 (-7.05%)
GOOGL   1,314.95 (-5.43%)
AMZN   1,884.30 (-4.81%)
CGC   18.44 (-6.96%)
NVDA   252.60 (-5.62%)
BABA   205.03 (-1.78%)
MU   50.58 (-3.42%)
GE   10.39 (-5.11%)
TSLA   679.00 (-12.81%)
AMD   44.01 (-7.33%)
T   35.73 (-3.69%)
ACB   1.45 (-3.97%)
F   6.97 (-3.33%)
NFLX   371.71 (-1.99%)
PRI   114.78 (-4.46%)
BAC   29.13 (-4.90%)
DIS   118.04 (-4.31%)
GILD   72.66 (-2.73%)
Log in

NASDAQ:VRAY - Viewray Stock Price, Forecast & News

$2.91
-0.15 (-4.90 %)
(As of 02/27/2020 04:00 PM ET)
Today's Range
$2.91
Now: $2.91
$3.11
50-Day Range
$2.70
MA: $3.17
$3.81
52-Week Range
$2.12
Now: $2.91
$9.76
Volume1.66 million shs
Average Volume3.20 million shs
Market Capitalization$289.27 million
P/E RatioN/A
Dividend YieldN/A
Beta1.23
ViewRay, Inc designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company's software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered. Read More…

Industry, Sector and Symbol

Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:VRAY
CUSIPN/A
Phone440-703-3210

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$80.96 million
Book Value$1.75 per share

Profitability

Net Income$-76,400,000.00
Net Margins-110.61%

Miscellaneous

EmployeesN/A
Market Cap$289.27 million
Next Earnings Date3/12/2020 (Confirmed)
OptionableOptionable

Receive VRAY News and Ratings via Email

Sign-up to receive the latest news and ratings for VRAY and its competitors with MarketBeat's FREE daily newsletter.


Viewray (NASDAQ:VRAY) Frequently Asked Questions

What is Viewray's stock symbol?

Viewray trades on the NASDAQ under the ticker symbol "VRAY."

How were Viewray's earnings last quarter?

Viewray Inc (NASDAQ:VRAY) released its quarterly earnings data on Tuesday, November, 12th. The company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.06. The company had revenue of $20.90 million for the quarter, compared to analysts' expectations of $20.66 million. Viewray had a negative return on equity of 75.41% and a negative net margin of 110.61%. Viewray's revenue was up 18.1% compared to the same quarter last year. During the same period last year, the firm posted ($0.39) earnings per share. View Viewray's Earnings History.

When is Viewray's next earnings date?

Viewray is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for Viewray.

How can I listen to Viewray's earnings call?

Viewray will be holding an earnings conference call on Thursday, March 12th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

What guidance has Viewray issued on next quarter's earnings?

Viewray updated its fourth quarter 2019 Pre-Market earnings guidance on Monday, January, 13th. The company provided EPS guidance of for the period. The company issued revenue guidance of $17-17 million, compared to the consensus revenue estimate of $18.27 million.

What price target have analysts set for VRAY?

9 Wall Street analysts have issued 12 month target prices for Viewray's stock. Their forecasts range from $5.00 to $9.00. On average, they anticipate Viewray's stock price to reach $6.44 in the next twelve months. This suggests a possible upside of 121.5% from the stock's current price. View Analyst Price Targets for Viewray.

What is the consensus analysts' recommendation for Viewray?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Viewray in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Viewray.

What are Wall Street analysts saying about Viewray stock?

Here are some recent quotes from research analysts about Viewray stock:
  • 1. According to Zacks Investment Research, "ViewRay Inc. is a medical device company. The company develops advanced radiation therapy technology for the treatment of cancer. MRIdian system provides continuous soft-tissue imaging during treatment. ViewRay Inc. is headquartered in Oakwood Village, Ohio. " (2/25/2020)
  • 2. Northland Securities analysts commented, "We remain confident in our analysis of the clinical benefits of MRgRT, and this study is another data point towards long-term validation." (8/19/2019)

Has Viewray been receiving favorable news coverage?

News headlines about VRAY stock have been trending extremely negative on Thursday, InfoTrie reports. InfoTrie identifies negative and positive press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Viewray earned a coverage optimism score of -4.2 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the next several days. View News Stories for Viewray.

Who are some of Viewray's key competitors?

What other stocks do shareholders of Viewray own?

When did Viewray IPO?

(VRAY) raised $52 million in an IPO on the week of April 6th 2015. The company issued 4,000,000 shares at $12.00-$14.00 per share. Cowen and Company and Stifel served as the underwriters for the IPO and BTIG and Brean Capital were co-managers.

Who are Viewray's major shareholders?

Viewray's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Fosun International Ltd (23.96%), FMR LLC (21.79%), Artisan Partners Limited Partnership (6.09%), Broadfin Capital LLC (5.61%), Bamco Inc. NY (2.00%) and State Street Corp (1.43%). Company insiders that own Viewray stock include Fmr Llc, International Ltd Fosun, James F Dempsey, Orbimed Advisors Llc, Scott William Drake and Shahriar Matin. View Institutional Ownership Trends for Viewray.

Which major investors are selling Viewray stock?

VRAY stock was sold by a variety of institutional investors in the last quarter, including Bank of America Corp DE, Barclays PLC, New York State Common Retirement Fund, UBS Asset Management Americas Inc., Artisan Partners Limited Partnership, Goldman Sachs Group Inc., Royce & Associates LP and Virtu Financial LLC. View Insider Buying and Selling for Viewray.

Which major investors are buying Viewray stock?

VRAY stock was bought by a variety of institutional investors in the last quarter, including FMR LLC, Fosun International Ltd, Broadfin Capital LLC, Bamco Inc. NY, Marshall Wace North America L.P., Driehaus Capital Management LLC, Geode Capital Management LLC and Candriam Luxembourg S.C.A.. Company insiders that have bought Viewray stock in the last two years include International Ltd Fosun, Scott William Drake and Shahriar Matin. View Insider Buying and Selling for Viewray.

How do I buy shares of Viewray?

Shares of VRAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Viewray's stock price today?

One share of VRAY stock can currently be purchased for approximately $2.91.

How big of a company is Viewray?

Viewray has a market capitalization of $289.27 million and generates $80.96 million in revenue each year. The company earns $-76,400,000.00 in net income (profit) each year or ($0.98) on an earnings per share basis. View Additional Information About Viewray.

What is Viewray's official website?

The official website for Viewray is http://www.viewray.com/.

How can I contact Viewray?

Viewray's mailing address is 2 THERMO FISHER WAY, OAKWOOD VILLAGE OH, 44146. The company can be reached via phone at 440-703-3210 or via email at [email protected]


MarketBeat Community Rating for Viewray (NASDAQ VRAY)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  259 (Vote Outperform)
Underperform Votes:  196 (Vote Underperform)
Total Votes:  455
MarketBeat's community ratings are surveys of what our community members think about Viewray and other stocks. Vote "Outperform" if you believe VRAY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VRAY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel